Core Viewpoint - The National Medical Products Administration is set to approve 76 innovative drugs by 2025, marking a significant increase in the diversity of therapeutic options available in China [1] Group 1: Drug Approval Statistics - A total of 76 innovative drugs will be approved, including 47 chemical drugs and 23 biological products [1] - Among the biological products, there are 10 antibody drugs, 4 recombinant proteins, 3 cell gene therapies, 3 antibody-drug conjugates, 1 gene therapy, and 1 peptide [1] - The approval of these drugs represents a record high and indicates a trend towards accelerated market entry of diverse innovative therapies in China [1] Group 2: Impact on Patients - The increase in approved innovative drugs will significantly enrich the clinical treatment options available to domestic patients [1]
2025年中国批准上市创新药 30款已纳入医保
Zheng Quan Shi Bao Wang·2026-01-20 05:31